IN8bio, Inc. (INAB)
Develops immune cell treatments using gamma-delta T cells to fight cancer and autoimmune diseases.
$1.11-0.07%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-47.4%
The outlook
INAB is trading near its 52-week low, well below both its 50- and 200-day moving averages, while analyst sentiment is bearish overall. The average analyst price target sits roughly 463% above the current price, though coverage appears thin given the wide gap between current data and targets. The stock shows minimal recent momentum.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +463% vs current price
Analyst price target
~12-month · 4 analysts$6.25average target+463.1% vs now
Now $1.11
Low $4.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$10.6M
52-wk high
$2.73
52-wk low
$1.10
50-day avg
$1.45
200-day avg
$1.73
Trailing P/E
—